Managers / Q4 2021 · view latest →
TRV GP II, LLC
CIK 0001614073 · THIRD ROCK VENTURES, 29 NEWBURY STREET, 3RD FLOOR, BOSTON, MA, 02116 · 617-585-2000
Summary
Trv GP II, LLC reported $24M in U.S.-listed holdings across 2 positions for Q4 2021.
The portfolio is heavily concentrated: Jounce Therapeutics alone accounts for 93.2% of reported value.
The book was largely unchanged from Q3 2021.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 100.0% · $24M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| JOUNCE THERAPEUTICS, INC. | HELD | +0 | 2.70M | +$2M | $23M |
| ALLENA PHARMACEUTICALS, INC. | HELD | +0 | 2.79M | −$864,000 | $2M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | JOUNCE THERAPEUTICS, INC. | COM | 93.16% | $23M | 2.70M |
| 2 | ALLENA PHARMACEUTICALS, INC. | COM | 6.84% | $2M | 2.79M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2022 | $1M | 1 | Nov 3, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $5M | 2 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $10M | 2 | May 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $24M | 2 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $23M | 2 | Nov 5, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $34M | 2 | Aug 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $158M | 3 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $144M | 3 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $154M | 3 | Nov 6, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $135M | 3 | Aug 7, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $93M | 3 | May 11, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $97M | 2 | Feb 5, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $45M | 2 | Nov 4, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $62M | 2 | Aug 6, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $153M | 3 | May 3, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 3 additional managers.
- Mark Levin028-18439
- Kevin P. Starr028-18438
- Robert I. Tepper028-18419
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.